

13 May 2024

News release

Availability of conversion capital for UBS Group AG Additional Tier 1 instruments issued since November 2023

Zurich, 13 May 2024 – Following shareholder approval of the creation of conversion capital and amendments to the Articles of Association at UBS Group AG's Annual General Meeting on 24 April 2024, a Conversion Capital Availability Event, as defined in the terms and conditions of the relevant instrument, occurred on 10 May 2024 for the below listed four series of UBS Group AG Additional Tier 1 instruments. As a result, as from such date, these instruments are subject to equity conversion (and no longer subject to write-down) upon the occurrence of a trigger event or a viability event.

<u>ISIN</u>	<u>CUSIP</u>	<u>Issuance Date</u>	<u>Title of Instrument</u>	<u>Aggregate Principal Amount Outstanding</u>
US902613BE74 / USH42097ER43 (144A / Reg S)	902613 BE7 / H42097 ER4 (144A / Reg S)	13 November 2023	9.250 per cent. Tier 1 Capital Notes	USD 1,750,000,000
US902613BF40 / USH42097ES26 (144A / Reg S)	902613 BF4 / H42097 ES2 (144A / Reg S)	13 November 2023	9.250 per cent. Tier 1 Capital Notes	USD 1,750,000,000
US902613BK35 / USH42097EW38 (144A / Reg S)	902613 BK3 / H42097 EW3 (144A / Reg S)	12 February 2024	7.750 per cent. Tier 1 Capital Notes	USD 1,000,000,000
CH1325807860	N/A	21 February 2024	5.750 per cent. Tier 1 Capital Notes	SGD 650,000,000

UBS Group AG

Investor contact

Switzerland: +41-44-234 41 00

Media contact

Switzerland: +41-44-234 85 00

UK: +44-207-567 47 14

Americas: +1-212-882 58 58

APAC: +852-297-1 82 00

www.ubs.com/media

Disclaimer

This announcement is intended solely for information purposes and does not constitute an offer of securities for sale in the United States or any other jurisdiction. No investment decision relating to securities should be made on the basis of this document. The instruments and any ordinary shares that may be delivered upon conversion have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act") or with any securities regulatory authority of any state or other jurisdiction in the United States. The instruments and any ordinary shares that may be delivered upon conversion may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act.

This announcement contains statements that may constitute "forward-looking statements". While these forward-looking statements represent our judgments and expectations concerning the matters described, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. For a discussion of the risks and uncertainties that may affect UBS please refer to the "Risk Factors" and other sections of UBS's most recent Annual Report on Form 20-F, quarterly reports and other information furnished to or filed with the US Securities and Exchange Commission on Form 6-K. UBS is not under any obligation to (and expressly disclaims any obligation to) update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.